The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

June 12, 2015

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

September 18, 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

September 09, 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising treatment landscape for patients with chronic lymphocytic leukemia.

August 25, 2014

Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

July 28, 2014

Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the impact ibrutinib has had on treating hematologic malignancies.

July 24, 2014

Tanios Bekaii-Saab, MD, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

July 15, 2014

Jennifer Woyach, MD, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations.

May 22, 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, describes the BR-002 trial for patients with breast cancer.

April 10, 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the potential to cure patients with metastatic breast cancer.

March 14, 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the use of ablative radiotherapy in patients with metastatic breast cancer.

October 23, 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

October 03, 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

September 20, 2013

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL).

August 23, 2013

Jennifer Woyach, MD, discusses peripheral lymphocytosis in patients with chronic lymphocytic leukemia after they take ibrutinib.

August 15, 2013

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

July 25, 2013

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, describes variations in the accuracy and availability of genetic testing technologies.